Adbry (tralokinumab-ldrm) is an interleukin-13 (IL-13) antagonist biologic therapy administered by subcutaneous injection, indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Adbry selectively binds to IL-13, a key cytokine involved in the inflammatory response of AD, blocking its interaction with IL-13 receptors to reduce inflammation and skin barrier dysfunction. The package insert specifically mentions the following adverse events: upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia. Patients should be monitored for signs of hypersensitivity reactions, conjunctivitis, and keratitis. Live vaccines should be avoided during treatment with Adbry. It can be incorporated into a broader treatment strategy for atopic dermatitis, offering a targeted approach for patients who have not responded to topical therapies. Adbry may be used as monotherapy or in combination with topical corticosteroids, providing flexibility in managing both acute and chronic symptoms. Its selective inhibition of IL-13, without affecting IL-4, differentiates it from other biologics in the AD treatment landscape, making it a valuable long-term therapy option for eligible patients.